Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 20:03:32 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Orphazyme - Bull story below Bear price

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Orphazyme - Bull story below Bear price

2020-12-17 08:17:00

Redeye revisits the Orphazyme case in light of exceptional news flow in the first half of 2021. We reiterate our positive fundamental view while raising fair value. Although the stock is now trading below our Bear Case, we see no intrinsic reason for its underperformance and expect the attractive pipeline-in-a-product – which holds blockbuster potential – to lift it.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/